Filing Details
- Accession Number:
- 0001415889-24-001589
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-01-19 16:17:44
- Reporting Period:
- 2024-01-18
- Accepted Time:
- 2024-01-19 16:17:44
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1649094 | Vaxcyte Inc. | PCVX | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1230724 | Andrew Guggenhime | C/O Vaxcyte, Inc. 825 Industrial Road, Ste. 300 San Carlos CA 94070 | President And Cfo | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-01-18 | 8,000 | $5.35 | 87,474 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-01-18 | 4,387 | $60.28 | 83,087 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-01-18 | 3,127 | $61.19 | 79,960 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-01-18 | 463 | $61.88 | 79,497 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-01-18 | 23 | $63.35 | 79,474 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2024-01-18 | 8,000 | $0.00 | 8,000 | $5.35 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 384,827 | 2030-05-11 | No | 4 | M | Direct |
Footnotes
- The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted June 30, 2023.
- The price reported is a weighted-average price. The shares were sold at prices ranging from $59.77 to $60.60. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- The price reported is a weighted-average price. The shares were sold at prices ranging from $60.80 to $61.76. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- The price reported is a weighted-average price. The shares were sold at prices ranging from $61.84 to $62.305. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- 1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter.
Billionaire Hedge Funds
